Cargando…

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component

The capsular group B meningococcal (MenB) four component vaccine (4CMenB) has been licensed for the prevention of invasive disease caused by MenB. The vaccine causes fever in infants, particularly when given in combination (concomitant) with other routinely-administered vaccines (routine), such as t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheerin, Dylan, O’Connor, Daniel, Dold, Christina, Clutterbuck, Elizabeth, Attar, Moustafa, Rollier, Christine S., Sadarangani, Manish, Pollard, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760121/ https://www.ncbi.nlm.nih.gov/pubmed/31551511 http://dx.doi.org/10.1038/s41598-019-50310-0

Ejemplares similares

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
por: Esposito, Susanna, et al.
Publicado: (2015)

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
por: Leduc, Isabelle, et al.
Publicado: (2020)

Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States
por: Banzhoff, Angelika
Publicado: (2017)

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017)

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
por: O’Ryan, Miguel, et al.
Publicado: (2013)

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
por: Bodini, Margherita, et al.
Publicado: (2020)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents
por: Biolchi, Alessia, et al.
Publicado: (2020)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
por: Kesanopoulos, Konstantinos, et al.
Publicado: (2018)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
por: Biolchi, Alessia, et al.
Publicado: (2019)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
por: Marshall, Helen S., et al.
Publicado: (2021)

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022
por: Rodrigues, C. M. C., et al.
Publicado: (2023)

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model
por: Argante, Lorenzo, et al.
Publicado: (2021)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
por: Gönüllü, Erdem, et al.
Publicado: (2019)

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries
por: Abad, Raquel, et al.
Publicado: (2016)

Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2021)

The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study
por: Davis, Kimberly, et al.
Publicado: (2019)

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
por: Veggi, Daniele, et al.
Publicado: (2020)

7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains
por: Biolchi, Alessia, et al.
Publicado: (2020)

An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol
por: Marshall, Helen S., et al.
Publicado: (2022)

Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Neisseria meningitidis Strains and Their Predicted Coverage by the 4CMenB Vaccine
por: Tsang, Raymond S. W., et al.
Publicado: (2020)

Correction to: Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2022)

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans
por: Viviani, Viola, et al.
Publicado: (2023)

Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial
por: Rollier, Christine S., et al.
Publicado: (2022)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
por: Sereikaitė, Emilija, et al.
Publicado: (2023)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
por: Stella, Maria, et al.
Publicado: (2019)

B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis
por: Marshall, Helen S, et al.
Publicado: (2019)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
por: Fazio, Cecilia, et al.
Publicado: (2021)

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS
por: Tozer, Sarah J., et al.
Publicado: (2021)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
por: Sheerin, Dylan, et al.
Publicado: (2022)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
por: Graña, María Gabriela, et al.
Publicado: (2021)

02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections
por: Garcia, Yara Ruiz, et al.
Publicado: (2021)

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
por: Zafack, Joseline Guetsop, et al.
Publicado: (2019)

An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol
por: Thng, Caroline, et al.
Publicado: (2023)

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)
por: Azzari, Chiara, et al.
Publicado: (2020)

Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
por: Bartolini, E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mvmbku0m3uc6k839rrkhfg8p4e